Theravance Biopharma(TBPH) - 2023 Q2 - Earnings Call Transcript

related to guidance. We're slightly below for R&D and slightly above, but all within the ranges that we've provided before. So hopefully, that provides a bit of color for you, David. David Risinger Operator I think that -- go ahead, Aziz. So Rhonda, do you have any additional comments there? And then just one final question. Now that the PIFR-2 readout is really sort of getting close, how should we think, if we get the outcome that we expect to get -- how should we think about that? Or how -- what's the sor ...